Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.